Literature DB >> 29016951

Compliance with Opioid Therapy: Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer Pain.

Dhanalakshmi Koyyalagunta1, Eduardo Bruera2, Mitchell P Engle1, Larry Driver1, Wenli Dong3, Chris Demaree4, Diane M Novy1.   

Abstract

Background: Because an increase of patients who misuse opioids has been identified in our cancer clinical setting through urine drug testing (UDT) and the Screener and Opioid Assessment for Patient's with Pain-Short Form (SOAPP-SF), we conducted this retrospective cohort study to identify patient characteristics that are associated with UDT that indicates noncompliance.
Methods: Over a two-year period, 167 of 8,727 patients (2.4%) seen in the pain clinic and who underwent UDT were evaluated to determine compliance with prescribed opioid regimens. Descriptive clinical and demographic data were collected, and group differences based on compliance with opioid therapy were evaluated.
Results: Fifty-eight percent of the patients were noncompliant with their prescribed opioid therapy. Noncompliant patients were younger than compliant patients, with a median age of 46 vs 49 years (P = 0.0408). Noncompliant patients were more likely to have higher morphine equivalent daily doses; however, the difference was not statistically significant. Patients with a history of alcohol (ETOH) (P = 0.0332), illicit drug use (P = 0.1014), and smoking (P = 0.4184) were more likely noncompliant. Univariate regression analysis showed that a history of ETOH use (P = 0.034), a history of anxiety (P = 0.027), younger age (P = 0.07), and a SOAPP-SF score of 4 or higher (P = 0.05) were associated with an abnormal UDT. Conclusions: History of ETOH use, anxiety, high SOAPP-SF score, and younger age were associated with UDT that indicates noncompliance. Given the very small percentage of UDT testing, it is quite likely that a significant number of patients who did not undergo UDT were also nonadherent with treatment recommendations.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29016951      PMCID: PMC6279272          DOI: 10.1093/pm/pnx178

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  49 in total

1.  Screening for substance abuse risk in cancer patients using the Opioid Risk Tool and urine drug screen.

Authors:  Joshua S Barclay; Justine E Owens; Leslie J Blackhall
Journal:  Support Care Cancer       Date:  2014-02-23       Impact factor: 3.603

Review 2.  Cancer pain management: safe and effective use of opioids.

Authors:  Eduardo Bruera; Judith A Paice
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

3.  Predictors of urine drug testing for patients with chronic pain: Results from a national cohort of U.S. veterans.

Authors:  Benjamin J Morasco; Dawn Peters; Erin E Krebs; Anne E Kovas; Kyle Hart; Steven K Dobscha
Journal:  Subst Abus       Date:  2015-10-30       Impact factor: 3.716

4.  Chemical coping versus pseudoaddiction in patients with cancer pain.

Authors:  Jung Hye Kwon; Kimberson Tanco; David Hui; Akhila Reddy; Eduardo Bruera
Journal:  Palliat Support Care       Date:  2014-02-13

5.  Aberrant Opioid Use and Urine Drug Testing in Outpatient Palliative Care.

Authors:  Joseph A Arthur; Ali Haider; Tonya Edwards; Jessica Waletich-Flemming; Suresh Reddy; Eduardo Bruera; David Hui
Journal:  J Palliat Med       Date:  2016-05-12       Impact factor: 2.947

6.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

7.  Gender differences in risk factors for aberrant prescription opioid use.

Authors:  Robert N Jamison; Stephen F Butler; Simon H Budman; Robert R Edwards; Ajay D Wasan
Journal:  J Pain       Date:  2009-11-27       Impact factor: 5.820

8.  Interpreting urine drug tests: prevalence of morphine metabolism to hydromorphone in chronic pain patients treated with morphine.

Authors:  Ajay D Wasan; Edward Michna; David Janfaza; Shelly Greenfield; Christian J Teter; Robert N Jamison
Journal:  Pain Med       Date:  2007-08-28       Impact factor: 3.750

9.  Do Palliative Care Clinics Screen for Substance Abuse and Diversion? Results of a National Survey.

Authors:  Paul D Tan; Joshua S Barclay; Leslie J Blackhall
Journal:  J Palliat Med       Date:  2015-06-05       Impact factor: 2.947

10.  Risk stratification of opioid misuse among patients with cancer pain using the SOAPP-SF.

Authors:  Dhanalakshmi Koyyalagunta; Eduardo Bruera; Carrie Aigner; Harun Nusrat; Larry Driver; Diane Novy
Journal:  Pain Med       Date:  2013-04-30       Impact factor: 3.750

View more
  5 in total

Review 1.  Opioid Prescribing in an Opioid Crisis: What Basic Skills Should an Oncologist Have Regarding Opioid Therapy?

Authors:  Joseph Arthur; Akhila Reddy
Journal:  Curr Treat Options Oncol       Date:  2019-04-01

Review 2.  Urine Drug Testing in Cancer Pain Management.

Authors:  Joseph A Arthur
Journal:  Oncologist       Date:  2019-10-11

Review 3.  A systematic review of assessment approaches to predict opioid misuse in people with cancer.

Authors:  Robyn Keall; Paul Keall; Carly Kiani; Tim Luckett; Richard McNeill; Melanie Lovell
Journal:  Support Care Cancer       Date:  2022-02-15       Impact factor: 3.359

4.  Identifying Prevalence of and Risk Factors for Abnormal Urine Drug Tests in Cancer Pain Patients.

Authors:  Kelly E Leap; Grant H Chen; Jasme Lee; Kay See Tan; Vivek Malhotra
Journal:  J Pain Symptom Manage       Date:  2020-12-01       Impact factor: 5.576

5.  Patient-reported reasons for and predictors of noncompliance with compression stockings in a randomized trial of stockings to prevent postthrombotic syndrome.

Authors:  Andrew J Dawson; Arash Akaberi; Jean-Philippe Galanaud; David R Morrison; Susan R Kahn
Journal:  Res Pract Thromb Haemost       Date:  2019-12-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.